<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04410315</url>
  </required_header>
  <id_info>
    <org_study_id>Prosp.Laktat.Tumorkraniotomi</org_study_id>
    <nct_id>NCT04410315</nct_id>
  </id_info>
  <brief_title>Hyperlactatemia During and After Tumorcraniotomy</brief_title>
  <official_title>Elevated Serum-lactate in Patients With Brain Tumor During and After Elective Craniotomy: an Observational Clinical Study of Postoperative Patient Outcome.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rigshospitalet, Denmark</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rigshospitalet, Denmark</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to investigate the association between hyperlactatemia and neurological&#xD;
      disability, length-of-stay and mortality in patients who undergo tumorcraniotomy. The risk&#xD;
      factors that induce lactat accumulation will also be explored.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Hyperlactatemia is a frequent occurrence in brain tumor surgery. The existing studies,&#xD;
      however, are all retrospective, reporting varying effects on clinical outcome. One study&#xD;
      reported new neurological deficitis, some found an association with extended hospital stay,&#xD;
      while others found no association with outcome. It is therefore important to conduct a&#xD;
      prospective study of hyperlactatemia in this patientgroup.&#xD;
&#xD;
      Participants in this study will follow the standard treatment protocol for tumorcraniotomy,&#xD;
      aside from 2-3 additional, perioperative blodgas analyses and 2 standardized measurements of&#xD;
      neurological disability.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 28, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2026</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Neurological disability</measure>
    <time_frame>Change from baseline mRS at 30 days after surgery</time_frame>
    <description>Modified Rankin Scale (Scoring 0-6, high scores meaning worse outcome)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Length of hospital stay</measure>
    <time_frame>1 year</time_frame>
    <description>In days from admission to discharge.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>After 30 days, 6 months and 5 years</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">450</enrollment>
  <condition>Hyperlactatemia</condition>
  <condition>Brain Tumor</condition>
  <condition>Surgery</condition>
  <condition>Anesthesia</condition>
  <arm_group>
    <arm_group_label>Tumorcraniotomy patients</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Serum-lactate &lt; 2,2 mmol/L</intervention_name>
    <description>Bloodgas analysis every hour from start surgery until recovery ward discharge</description>
    <arm_group_label>Tumorcraniotomy patients</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Serum-lactate &gt;/= 2,2 mmol/L</intervention_name>
    <description>Bloodgas analysis every hour from start surgery until recovery ward discharge</description>
    <arm_group_label>Tumorcraniotomy patients</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients undergoing tumorcraniotomy&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age &gt;/= 18 years&#xD;
&#xD;
          -  Must undergo elective tumor craniotomy&#xD;
&#xD;
          -  Understand oral and written Danish&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Adults with incapacity&#xD;
&#xD;
          -  Stereotactic biopsy&#xD;
&#xD;
          -  Lack of informed and signed consent to participate in study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Department of Neuroanesthesiology, Rigshospitalet</name>
      <address>
        <city>Copenhagen</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alexandra Vassilieva, MD</last_name>
      <phone>+4526525373</phone>
      <email>alexandra.vassilieva@regionh.dk</email>
    </contact>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>May 14, 2020</study_first_submitted>
  <study_first_submitted_qc>May 29, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">June 1, 2020</study_first_posted>
  <last_update_submitted>September 20, 2021</last_update_submitted>
  <last_update_submitted_qc>September 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Rigshospitalet, Denmark</investigator_affiliation>
    <investigator_full_name>Alexandra Vassilieva</investigator_full_name>
    <investigator_title>Principal investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Brain Neoplasms</mesh_term>
    <mesh_term>Hyperlactatemia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

